Evidence map›Paper›PMID 39833820›Full record

ArticleBMC urology2025

Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer.

Fang Cao, Qing Li, Tianyu Xiong, Yingjie Zheng, Tian Zhang, Mulan Jin, Liming Song, Nianzeng Xing, Yinong Niu

Abstract read
In one paragraph

Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fang CaoDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Qing LiDepartment of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Tianyu XiongDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Yingjie ZhengDepartment of Radiotherapy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Tian ZhangDepartment of Radiotherapy, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Mulan JinDepartment of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Liming SongDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Nianzeng XingDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. xingnianzeng@126.com.
Yinong NiuDepartment of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. niuyinong@mail.ccmu.edu.cn.

Funding

the National Natural Science Foundation of China NSFC 82170783
6 · The paper itself

Abstract

backgroundIntraductal carcinoma of the prostate cancer (IDC-P), as a specific pathological type in prostate cancer which usually implies a poor prognosis. IDC-P morphology can be divided into two subtypes: Pattern 1, sieve like or loose cribriform structures; Pattern 2, solid or dense cribriform structures. The purpose of the study is to identify the impact of IDC-P and its subtypes on the prognosis of patients undergoing post-operative radiotherapy (PORT) after radical prostatectomy (RP) due to localized prostate cancer(PCa).

methodsWe performed a retrospective study of patients with localized PCa treated by RP followed by PORT or not. Patients with localized PCa who underwent RP from August 2013 to December 2020 were included in this study. INCLUSION CRITERIA: post-operative PSA dropped to less than 0.1 ng/ml after RP, had at least 1 poor prognostic risk factor (including high Gleason's grouping; positive surgical margins; seminal vesicle invasion; extraprostatic extension; and lympho-vascular invasion), and were eligible for adjuvant radiotherapy.; In this study, patients who underwent salvage radiotherapy after RP due to biochemical recurrence (two consecutive PSA > 0.2 ng/ml) were also included, but not patients with persistent postoperative PSA > 0.1 ng/ml. EXCLUSION CRITERIA: patients using other types of therapy prior to biochemical recurrence. Screening cases with pathological results of intraductal carcinoma, subtyping was completed by a pathologist, grouped by intraductal carcinoma (+/-; pattern 1/ 2) and treatment regimen (RP + PORT / RP only), Kaplan-Meier curves were plotted based on the time to biochemical recurrence-free and overall survival of the patients, and Cox regression analyses were performed. Finally, based on the results of Cox regression analysis, we initially predicted the probability of biochemical recurrence and death of the patients by plotting the nomogram.

resultsA total of 139 patients were included in this study with a median follow-up of 61.5 months. K-M curves showed that patients with "IDC-P (+) RP only" had the worst prognosis; patients with IDC-P could have a survival benefit after receiving PORT; whereas patients with non-intraductal carcinoma had a better prognosis than the above patients with or without PORT. In addition, patients with IDC-P(+) pattern 2 were more likely to experience biochemical recurrence and death. Multivariate Cox regression analysis showed that pattern 2 was a risk factor for biochemical recurrence and death. Other BCR-related risk factors in the research: Gleason grading group 5 (HR = 3.343, 95% CI: 1.616-6.916, P = 0.001), PM (HR = 2.124, 95% CI: 1.044-4.320,P = 0.038) and PORT (HR = 0.266, 95%CI: 0.109-0.647, P = 0.004). Other OS-related risk factors in the research: Grading group 5 (HR = 3.642, 95%CI:1.475-8.991, P = 0.005), SVI (HR = 2.522, 95% CI: 1.118-5.691, P = 0.026) and PORT (HR = 0.319, 95%CI: 0.107-0.949, P = 0.040).

conclusionPatients suffering from localized prostate cancer with IDC-P(+), especially IDC-P pattern 2, are more susceptible to biochemical recurrence and death after radical prostatectomy. While postoperative radiotherapy can alleviate the negative prognostic impact from IDC-P. It is implied that IDC-P can also be an indicator to be considered in PORT decision making to some extent.

Indexed as

Carcinoma, Intraductal, NoninfiltratingProstatic NeoplasmsAgedHumansMaleMiddle AgedPrognosisProstatectomyRadiotherapy, AdjuvantRetrospective StudiesIntraductal carcinomaProstate cancerRadiotherapy

Identifiers

PMID39833820
PMCPMC11748261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.